Related posts

Nervous markets await Nvidia
Investor Insights

This summary was created by AI, based on 33 opinions in the last 12 months.

UnitedHealth Group Inc. continues to be viewed as a strong player in the healthcare sector despite facing some regulatory pressures and volatility in the market. Analysts highlight the company's leadership position and pricing power, with expectations of steady earnings growth driven by an integrated business model and favorable demographic trends. Although recent controversies and government scrutiny are acknowledged, many experts believe these headwinds will ultimately dissipate. The stock has shown resilience, attracting both long-term investors and cautious speculators, with some urging to buy on weakness. Overall, UnitedHealth's fundamentals remain solid, supported by robust cash flow and a diversified business strategy, positioning it well for future growth.

Consensus
Buy
Valuation
Undervalued
DON'T BUY

A few weeks ago they warned they wouldn't meet their numbers. Today, they said they wouldn't meet their guidance. US insurance is changing with regulatory policy demands and medical loss ratios are staying high as people are using their plans more and more as an echo of Covid. The problem is UNH's concentration in the Medicare/Medicaid space

TOP PICK

Historical bastion of consistency. Last quarter it became inconsistent, with a 12% guidance down on EPS because utilization rates went up (they were unable, for some reason, to calculate this accurately). Just a small improvement in these metrics will boost the stock. 20 years of excellent execution, so this hiccup is a great time to buy. Yield is 2.2%.

(Analysts’ price target is $536.65)
WAIT

Major leader in the Medicare space. Recent rare miss on earnings, and he sold just before. Shares now well below 200-day MA, which is starting to trend down a little bit. Earnings growth rate now 6-7% going forward, at 14x forward PE.

Very oversold, around 25 RSI. At some point, shares will bottom and move higher. Be careful, shares seem to be in freefall right now. Doesn't see any major support levels. Wait for an opportunity, once it starts swinging up for real.

BUY

Good entry point for long-term hold; potential generational buying opportunity. Reason for the drop is that they were classifying clinic patients as less sick than they actually were. Resulted in recouping less revenue, to the tune of ~$500 per month per patient, amounting to ~$3+B. Keep an eye on how quickly this amount is recovered. Yield is 2.1%.

Be mindful that this doesn't turn into a bigger problem of something fundamentally changing in the ever-evolving US healthcare system. Facts could change.

BUY ON WEAKNESS

It will be under pressure for some time and he's been very negative on this stock, but at $400 you can start a position on it.

TOP PICK

Fallen angel. Disappointing quarter, severely lowered guidance for 2025. 80% of its business is healthcare insurance. Taking market share in every segment they operate in. Funding pressure on government-funded healthcare insurance is curtailing short-term profitability; but this is building long-term value for shareholders. Secular trends of demographics and morbidity in the US are tailwinds. 

Fortress-like balance sheet, A+ credit rating. Buying back shares prolifically with FCF. Trading at 15x PE vs. the 5-year average of 19.5x. Yield is 1.97%.

(Analysts’ price target is $553.00)
DON'T BUY

Has plunged 22% since reporting last Thursday and dragged the sector down. What in the world happened? They missed top and bottom lines, but worse they cut their full-year earnings forecast by 12%, citing high medical costs in its Medicare plans. The health profiles of many patients has been inaccurate., especially in their managed care business. Their medical care ratio was 84.8% in Q1 2025, but they guided full year at 87.5%. However, UNH's peers are faring better. UNH is having execution problems and is no longer best of breed.

BUY ON WEAKNESS

Down today, so an opportunity. The largest health insurer can do anything it wants under this presidency.

BUY

It reports Thursday. Not too high of a PE and not overly loved and purely domestic. It has pricing power.

BUY ON WEAKNESS

Is up 10% in the past month. Don't chase a red hot stock, but let it come in a bit (lower). Every time this spikes, it goes down. It's best of breed.

BUY

Near term, this can't trade at prior multiples given volatility. Anything healthcare is uncertain. He still believes in the $600 price target. Great management. They have growth.

HOLD

Leader in the space. Trades at 16x forward PE, 11% growth. Last 5 years, earnings have growth 12% a year. 200-day MA trending higher, but price is a bit below that, so technical signals are neutral. Integrated model strong. Pricing power. Down 24% from recent highs on regulatory concerns, overdone.

BUY ON WEAKNESS

Is down 20% in 6 months and trades at 6.5x EBITA vs. 12x historically, strong managers, $20 billion free cash flow and new share buybacks.

PARTIAL SELL

The DOJ is going after them for Medicare payments. Is taking some risk off the table.

BUY ON WEAKNESS
Enter now on weakness?

Yes. It was a top pick of his last spring. He doesn't think there will be much negative impact from Washington investigating their billing practices, though there remains headline risk. Fundamentals are improving, though they are paying out more for medical costs, which he hopes will normalize. It's trading below the market PE, when usually it trades above.

Showing 1 to 15 of 237 entries

UnitedHealth Group Inc(UNH-N) Rating

Ranking : 4 out of 5

Star iconStar iconStar iconStar iconStar empty icon

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 3

Total Signals / Votes : 9

Stockchase rating for UnitedHealth Group Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

UnitedHealth Group Inc(UNH-N) Frequently Asked Questions

What is UnitedHealth Group Inc stock symbol?

UnitedHealth Group Inc is a American stock, trading under the symbol UNH-N on the New York Stock Exchange (UNH). It is usually referred to as NYSE:UNH or UNH-N

Is UnitedHealth Group Inc a buy or a sell?

In the last year, 9 stock analysts published opinions about UNH-N. 3 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for UnitedHealth Group Inc.

Is UnitedHealth Group Inc a good investment or a top pick?

UnitedHealth Group Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for UnitedHealth Group Inc.

Why is UnitedHealth Group Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is UnitedHealth Group Inc worth watching?

9 stock analysts on Stockchase covered UnitedHealth Group Inc In the last year. It is a trending stock that is worth watching.

What is UnitedHealth Group Inc stock price?

On 2025-05-13, UnitedHealth Group Inc (UNH-N) stock closed at a price of $311.38.